Melissa Epperly

Melissa Epperly is a senior financial operating executive with nearly two decades of life sciences corporate development and financial experience. Ms. Epperly is currently CFO at Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Prior to her current position, she served as CFO of PsiOxus Therapeutics Ltd., a clinical-stage gene therapy cancer company. Prior to that, Ms. Epperly served as CFO and Head of Business Development at R-Pharm US, a commercial-stage oncology company. She previously served as a Director at Anchorage Capital Group, a credit-focused hedge fund; a Vice President at Goldman Sachs in equity research in New York and London where she built GS SUSTAIN; and a management consultant with Bain & Company. She began her career at Morgan Stanley in New York in healthcare investment banking.

Ms. Epperly holds a B.A. in Biochemistry and Economics from the University of Virginia and an M.B.A. from Harvard Business School.